UA42715C2 - Полінуклеотидна вакцина на основі плазмідної днк, імуногенна композиція(варіанти) - Google Patents

Полінуклеотидна вакцина на основі плазмідної днк, імуногенна композиція(варіанти)

Info

Publication number
UA42715C2
UA42715C2 UA95094152A UA95094152A UA42715C2 UA 42715 C2 UA42715 C2 UA 42715C2 UA 95094152 A UA95094152 A UA 95094152A UA 95094152 A UA95094152 A UA 95094152A UA 42715 C2 UA42715 C2 UA 42715C2
Authority
UA
Ukraine
Prior art keywords
plasmid dna
variants
polynucleotide vaccine
immunogenic composition
terminator
Prior art date
Application number
UA95094152A
Other languages
English (en)
Russian (ru)
Inventor
Джон Дж. Доннеллі
Джон Дж. ДОННЕЛЛИ
Варавані Дж. Дваркі
Варавани Дж. ДВАРКИ
Маргарет А. Ліу
Маргарет А. ЛИУ
Донна Л. Монтгомері
Донна Л. МОНТГОМЕРИ
С'юзанн Е. Паркер
Съюзанн Е. Паркер
Джон В. Шівер
Джон В. ШИВЕР
Джеффрі Б. Алмер
Джеффри Б. АЛМЕР
Original Assignee
Мерк Енд Ко., Інк.
Мерк Энд Ко., Инк.
Вікал Інкорпорейтед
Викал Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Енд Ко., Інк., Мерк Энд Ко., Инк., Вікал Інкорпорейтед, Викал Инкорпорейтед filed Critical Мерк Енд Ко., Інк.
Publication of UA42715C2 publication Critical patent/UA42715C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Полінуклеотидна вакцина на основі плазмідної ДНК містить регуляторну послідовність, яка являє собою промотор цитомегаловірусу з послідовністю інтрону А (1,63 т.п.н.), термінатор транскрипції, що являє собою термінатор транскрипції бичачого гормону росту (0,55 т.п.н.), бактеріальну область початку реплікації, що являє собою ori (0,64 т.п.н.) та маркер, що визначається, що являє собою ген стійкості до канаміцину (1,30 т.п.н.).
UA95094152A 1993-03-18 1994-03-14 Полінуклеотидна вакцина на основі плазмідної днк, імуногенна композиція(варіанти) UA42715C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3238393A 1993-03-18 1993-03-18
US8998593A 1993-07-08 1993-07-08
PCT/US1994/002751 WO1994021797A1 (en) 1993-03-18 1994-03-14 Nucleic acid pharmaceuticals

Publications (1)

Publication Number Publication Date
UA42715C2 true UA42715C2 (uk) 2001-11-15

Family

ID=26708344

Family Applications (1)

Application Number Title Priority Date Filing Date
UA95094152A UA42715C2 (uk) 1993-03-18 1994-03-14 Полінуклеотидна вакцина на основі плазмідної днк, імуногенна композиція(варіанти)

Country Status (22)

Country Link
EP (1) EP0620277A1 (uk)
JP (2) JP2812352B2 (uk)
CN (1) CN1119458A (uk)
AU (1) AU676258B2 (uk)
BG (1) BG63126B1 (uk)
BR (1) BR9406007A (uk)
CA (1) CA2119175A1 (uk)
CZ (1) CZ290315B6 (uk)
DZ (1) DZ1759A1 (uk)
FI (1) FI954329A0 (uk)
HR (1) HRP940175A2 (uk)
HU (1) HUT73397A (uk)
IL (1) IL108915A0 (uk)
NO (1) NO953649L (uk)
NZ (1) NZ263680A (uk)
PL (1) PL178626B1 (uk)
RO (1) RO117710B1 (uk)
SI (1) SI9420014A (uk)
SK (1) SK114295A3 (uk)
UA (1) UA42715C2 (uk)
WO (1) WO1994021797A1 (uk)
YU (1) YU12894A (uk)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US6911216B1 (en) 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
DE19512142A1 (de) * 1995-03-31 1996-10-02 Immuno Ag Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält
US6083925A (en) 1995-06-07 2000-07-04 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6017897A (en) * 1995-06-07 2000-01-25 Pasteur Merieux Connaught Canada Nucleic acid respiratory syncytial virus vaccines
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
US6204250B1 (en) 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
AU722326B2 (en) * 1997-02-14 2000-07-27 Merck & Co., Inc. Polynucleotide vaccine formulations
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
EP1105490A1 (en) 1998-08-20 2001-06-13 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein c of chlamydia
US6881723B1 (en) 1998-11-05 2005-04-19 Powderject Vaccines, Inc. Nucleic acid constructs
US7691389B2 (en) 1998-12-22 2010-04-06 Pfizer Inc Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7618797B2 (en) 1998-12-22 2009-11-17 Pfizer Inc Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
AU3593200A (en) 1999-02-09 2000-08-29 Powderject Vaccines, Inc. (mycobacterium tuberculosis), immunization
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
JP2001151698A (ja) * 1999-09-10 2001-06-05 Nichiko Pharmaceutical Co Ltd インフルエンザワクチン
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
EP1792995A3 (en) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia secretory locus orf and uses thereof
CA2408328C (en) 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
CA2687888A1 (en) * 2007-05-31 2008-12-11 Becton, Dickinson And Company Sequences and methods for detecting influenza a and influenza b virus
US8354230B2 (en) * 2007-12-21 2013-01-15 Quest Diagnostics Investments Inc. Multiplex detection assay for influenza and RSV viruses
EP2318044B1 (en) 2008-08-01 2015-12-02 Gamma Vaccines Pty Limited Influenza vaccines
US8894997B2 (en) 2009-04-30 2014-11-25 Vanderbilt University Monoclonal antibodies to influenza H1N1 virus uses thereof
SG168423A1 (en) * 2009-07-13 2011-02-28 Agency Science Tech & Res Influenza detection method and kit therefor
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低pcv-2組合物殺病毒活性之方法及具有改良免疫原性之pcv-2組合物
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
US10383835B2 (en) 2012-03-14 2019-08-20 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
ES2689878T3 (es) 2013-02-21 2018-11-16 Boehringer Ingelheim Vetmedica Gmbh Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento
KR102379951B1 (ko) * 2013-03-18 2022-03-31 오시벡스 에스에이에스 인플루엔자 핵단백질 백신
US9987348B2 (en) 2013-09-25 2018-06-05 Zoetis Services Llc PCV2B divergent vaccine composition and methods of use
KR20160132494A (ko) 2014-04-03 2016-11-18 베링거잉겔하임베트메디카인코퍼레이티드 돼지 유행성 설사 바이러스 백신
BR112017028224A2 (pt) 2015-08-31 2018-09-11 Boehringer Ingelheim Vetmedica Gmbh composição, e, método para proteger um leitão contra uma doença associada a pestivírus.
AU2016323106A1 (en) 2015-09-16 2018-03-29 Boehringer Ingelheim Animal Health USA Inc. Salmonella Choleraesuis-Salmonella Typhimurium vaccines
CN109715219B (zh) 2016-09-20 2024-03-01 勃林格殷格翰动物保健有限公司 犬腺病毒载体
EP3515480A1 (en) 2016-09-20 2019-07-31 Boehringer Ingelheim Vetmedica GmbH New swine influenza vaccine
UY37406A (es) 2016-09-20 2018-03-23 Boehringer Ingelheim Vetmedica Gmbh Nuevo sitio de inserción orf70 de ehv
CA3036293A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New promoters
MX2019005136A (es) 2016-11-03 2019-06-20 Boehringer Ingelheim Vetmedica Gmbh Vacuna contra el parvovirus porcino y el virus del sindrome respiratorio reproductivo porcino y metodos de produccion de esta.
KR102669319B1 (ko) 2016-11-03 2024-05-28 베링거잉겔하임베트메디카게엠베하 돼지 파보바이러스에 대한 백신
WO2018140766A2 (en) 2017-01-30 2018-08-02 Boehringer Ingelheim Vetmedica, Inc. Porcine coronavirus vaccines
CA3068052A1 (en) 2017-07-12 2019-01-17 Boheringer Ingelheim Animal Health Usa Inc. Senecavirus a immunogenic compositions and methods thereof
KR20200057742A (ko) 2017-09-23 2020-05-26 베링거잉겔하임베트메디카게엠베하 파라믹소바이러스과 발현 시스템
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
CN111712575B (zh) 2018-02-23 2024-07-19 勃林格殷格翰动物保健有限公司 表达外源猫副粘病毒基因的重组病毒载体系统及由其制备的疫苗
MX2020009722A (es) 2018-03-19 2021-01-29 Boehringer Ingelheim Vetmedica Gmbh Nuevo sitio de insercion ul43 de ehv.
CN111867625A (zh) 2018-03-19 2020-10-30 勃林格殷格翰动物保健有限公司 具有失活ul18和/或ul8的新ehv
CA3091982A1 (en) 2018-03-26 2019-10-03 Boehringer Ingelheim Animal Health USA Inc. Method of producing an immunogenic composition
WO2020058327A1 (en) 2018-09-20 2020-03-26 Boehringer Ingelheim Vetmedica Gmbh Modified pedv spike protein
EP3852800A1 (en) 2018-09-20 2021-07-28 Boehringer Ingelheim Vetmedica GmbH Intranasal vector vaccine against porcine epidemic diarrhea
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
WO2021158878A1 (en) 2020-02-06 2021-08-12 Boehringer Ingelheim Animal Health USA Inc. Polypeptides useful for detecting anti-rhabdovirus antibodies
CA3195910A1 (en) 2020-10-05 2022-04-14 Boehringer Ingelheim Vetmedica Gmbh Fusion protein useful for vaccination against rotavirus
US20220160864A1 (en) 2020-10-05 2022-05-26 Boehringer Ingelheim Animal Health USA Inc. Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof
US20240050555A1 (en) 2022-04-05 2024-02-15 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for vaccination against rotavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86354A0 (en) * 1987-05-22 1988-11-15 Orion Yhtymae Oy Episomal vector for the expression of selected dna fragments coding for optional polypeptides in mammalian cells and methods for the production thereof
ATE240401T1 (de) * 1989-03-21 2003-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit

Also Published As

Publication number Publication date
BG63126B1 (bg) 2001-04-30
BR9406007A (pt) 1996-01-02
SK114295A3 (en) 1996-02-07
WO1994021797A1 (en) 1994-09-29
JPH0795888A (ja) 1995-04-11
RO117710B1 (ro) 2002-06-28
EP0620277A1 (en) 1994-10-19
NO953649D0 (no) 1995-09-15
HUT73397A (en) 1996-07-29
FI954329A (fi) 1995-09-14
NO953649L (no) 1995-11-17
CN1119458A (zh) 1996-03-27
SI9420014A (en) 1996-08-31
AU676258B2 (en) 1997-03-06
HU9502702D0 (en) 1995-11-28
JPH10113194A (ja) 1998-05-06
JP2812352B2 (ja) 1998-10-22
CZ237395A3 (en) 1996-02-14
IL108915A0 (en) 1994-06-24
BG100006A (bg) 1996-12-31
PL178626B1 (pl) 2000-05-31
YU12894A (sh) 1997-12-05
PL310677A1 (en) 1995-12-27
AU5788994A (en) 1994-09-22
DZ1759A1 (fr) 2002-02-17
JP3608642B2 (ja) 2005-01-12
CZ290315B6 (cs) 2002-07-17
FI954329A0 (fi) 1995-09-14
HRP940175A2 (en) 1997-04-30
CA2119175A1 (en) 1994-09-19
NZ263680A (en) 1997-05-26

Similar Documents

Publication Publication Date Title
UA42715C2 (uk) Полінуклеотидна вакцина на основі плазмідної днк, імуногенна композиція(варіанти)
DE3276241D1 (en) Expression of polypeptides in yeast
DE3279030D1 (en) Novel vector plasmids
EP0249676A3 (en) Method for the expression of genes in plants
AU6893587A (en) Recombinant dna sequences, vectors containing them and method for the use thereof
GB9114259D0 (en) Plant derived enzyme and dna sequences
DE2862496D1 (en) Method for polypeptide production involving expression of a heterologous gene, recombinant microbial cloning vehicle containing said gene and bacterial culture transformed by said cloning vehicle
AU604743B2 (en) Phosphinothricin-resistance gene, and its use
GB9118759D0 (en) Recombinant dna
EP0332120A3 (en) Structural gene for membranebound aldehyde dehydrogenase, plasmid containing the same, acetic acid bacteria transformed with said plasmid, and acetic acid fermentation using said transformant
CA2072007A1 (en) Cloning Vector for Use in Lactic Acid Bacteria and a Method for Constructing the Same
DE3277631D1 (en) Recombinant plasmid and microorganism containing same
IE831099L (en) Cloning vehicles for polypeptide expression in microbial¹hosts
KR910001046A (ko) 비융합 단백질을 제조하기 위한 미생물내 발현용 발현벡터
DE3380878D1 (en) Method of heterologous cloning of gene in bacillus microorganism
EP0112012A3 (en) Recombinant DNA molecules
ES8306176A1 (es) Procedimiento para la preparacion de un vector hibrido y la clonacion de adn-ajeno en organismos hospetantes.
EP0068647A3 (en) Plasmids, plasmid hosts, and their preparation
DE3570694D1 (en) Recombinant saccharomyces
JPS5756495A (en) Novel dna-introduction vector and recombinant dna
GB2067574B (en) Microbiologically prepared polypeptide with the amino acid sequence of proinsulin of a primate dna and plasmids which code for this sequence microorganisms which contain this genetic information and processes for their preparation
WO1993018151A1 (fr) Element transposable originaire d'une bacterie du genre brevibacterium
HK192795A (en) A novel system of inducible positive regulation of use for production of heterologous proteins
EP0038156A3 (en) A plasmid and its microbiological preparation
GR3007612T3 (uk)